Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies

Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.

Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.

NLRs
Widespread Plant Immune Tactics
Widespread Plant Immune Tactics
Jef Akst | Feb 22, 2016
A survey of plant genomes reveals how different species trick pathogens into triggering their immune defenses.